Keywords: دیسیپیدمی آتروژنیک; Pre-diabetes; Hypertriglyceridemic waist; Atherogenic dyslipidemia; Secondary prevention; Fatal vascular events; EUROASPIRE;
مقالات ISI دیسیپیدمی آتروژنیک (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: دیسیپیدمی آتروژنیک; AD; atherogenic dyslipidemia; apoB100; apolipoprotein B100; CHD; coronary heart disease; hsCRP; high-sensitivity C-reactive protein; CV; cardiovascular; DM; diabetes mellitus; GP; general practitioner; HbA1c; glycated haemoglobin; HDL; high-density lipopr
Keywords: دیسیپیدمی آتروژنیک; Cardiovascular disease; Risk factor; Hypercholesterolemia; Atherogenic dyslipidemia; Statin;
Keywords: دیسیپیدمی آتروژنیک; Nonalcoholic fatty liver disease; Fatty liver index; Atherogenic dyslipidemia; Nuclear magnetic resonance spectroscopy; Lipoproteins;
Keywords: دیسیپیدمی آتروژنیک; Dislipidemia aterogénica; Fibratos; Fenofibrato; Triglicéridos; Riesgo cardiovascular; Atherogenic dyslipidemia; Fibrates; Fenofibrate; Triglycerides; Cardiovascular risk;
Keywords: دیسیپیدمی آتروژنیک; Diabetes; Metabolic syndrome; Obesity; Atherogenic dyslipidemia; Handedness
Keywords: دیسیپیدمی آتروژنیک; Nutraceuticals; Functional foods; Lipids; Atherogenic dyslipidemia
Keywords: دیسیپیدمی آتروژنیک; Atherogenic dyslipidemia; Lipoprotein subfraction profile; Small dense low-density lipoprotein; Glucose metabolism; Impaired fasting glucose;
Keywords: دیسیپیدمی آتروژنیک; Ovariectomy; Atherogenic dyslipidemia; Hepatic steatosis; Obesity; Soy isoflavones;
Keywords: دیسیپیدمی آتروژنیک; Hypertension; Atherogenic dyslipemia; Ambulatory blood pressure monitoring; Target organ damage; Blood pressure control; Hypertryglyceridemia; Hipertensión arterial; Dislipemia aterogénica; Monitorización ambulatoria de la presión arterial; Lesión de
Keywords: دیسیپیدمی آتروژنیک; Dyslipidemia; Combined dyslipidemia; Mixed dyslipidemia; Atherogenic dyslipidemia; Child; Adolescent; Obesity
Keywords: دیسیپیدمی آتروژنیک; Parental longevity; Diabetes; Insulin sensitivity; Atherogenic dyslipidemia; HDL-cholesterol; Apolipoprotein
Keywords: دیسیپیدمی آتروژنیک; Type 2 diabetes; Glycemic control; Duration of diabetes; Atherogenic dyslipidemia; Oral antidiabetic agents; Insulin therapy; Primary careDiabetes tipo 2; Control glucémico; Duración de la diabetes; Dislipemia aterogénica; Antidiabéticos orales; Insulinot
Keywords: دیسیپیدمی آتروژنیک; Coronary heart disease; Lipids; Cholesterol; Atherogenic dyslipidemia; Epidemiology
Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia
Keywords: دیسیپیدمی آتروژنیک; Atherosclerosis; Atherogenic dyslipidemia; Cholesterol efflux capacity; High-density lipoproteins; K-877; Pemafibrate; Postprandial hyperlipidemia; Reverse cholesterol transport; Selective peroxisome proliferator-activated receptor α modulator; Triglycer
Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease: A post hoc analysis of the AIM-HIGH trial
Keywords: دیسیپیدمی آتروژنیک; Metabolic syndrome; Cardiovascular disease; Diabetes mellitus; Atherogenic dyslipidemia; Extended-release niacin;
Consenso sobre tratamiento farmacológico de la dislipidemia aterogénica con terapia combinada estatina-fenofibrato
Keywords: دیسیپیدمی آتروژنیک; Asociación estatina-fenofibrato; Dislipidemia aterogénica; Terapia combinada hipolipemianteStatine-fenofibrate association; Atherogenic dyslipidemia; Lipid lowering combination therapy
APOA5 variants predispose hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis
Keywords: دیسیپیدمی آتروژنیک; APOA5; Polymorphisms; NMR; IMT; Atherogenic dyslipidemia;
Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities Study
Keywords: دیسیپیدمی آتروژنیک; Apolipoprotein C3 loss-of-function; Atherogenic dyslipidemia; Atherosclerosis Risk In Communities Study; Cardiovascular disease; Coronary heart disease; Ischemic stroke; Lipoprotein-associated phospholipase A2 activity; ApoB; apolipoprotein B; ApoC3 LOF;
Body mass index correlates with atherogenic lipoprotein profile even in nonobese, normoglycemic, and normolipidemic healthy men
Keywords: دیسیپیدمی آتروژنیک; BMI; Healthy participants; Atherogenic dyslipidemia; Lipoprotein; NMR;
Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes
Keywords: دیسیپیدمی آتروژنیک; Aspirin resistance; Non-HDL cholesterol; Atherogenic dyslipidemia; Diabetes;
Gender-specific associations of the APOA1 − 75G > A polymorphism with several metabolic syndrome components in Turkish adults
Keywords: دیسیپیدمی آتروژنیک; Apolipoprotein A1; Polymorphism; HDL-C; Atherogenic dyslipidemia; Blood pressure
Prevalence of atherogenic dyslipidemia: Association with risk factors and cardiovascular risk in Spanish working population. "ICARIA" study
Keywords: دیسیپیدمی آتروژنیک; Atherogenic dyslipidemia; Cardiovascular risk; Triglycerides; HDL;
Control glucémico en pacientes con diabetes mellitus tipo 2 en España
Keywords: دیسیپیدمی آتروژنیک; Diabetes tipo 2; Control glucémico; Duración de la diabetes; Dislipemia aterogénica; Antidiabéticos orales; Insulinoterapia; Atención primariaType 2 diabetes; Glycemic control; Duration of diabetes; Atherogenic dyslipidemia; Oral antidiabetic agents; Insu
Atherogenic dyslipidemia: prevalence and management in lipid clinics
Keywords: دیسیپیدمی آتروژنیک; Atherogenic dyslipidemia; HDL cholesterol; Epidemiology; Cardiovascular risk prevention; Lipid clinics; TriglyceridesDislipemia aterogénica; Colesterol HDL; Epidemiología; Prevención cardiovascular; Unidades de lípidos; Triglicéridos
Dislipidemia aterogénica en pacientes con diabetes mellitus tipo 1
Keywords: دیسیپیدمی آتروژنیک; Diabetes tipo 1; Alteraciones lipídicas; Dislipidemia aterogénica; Complicaciones macrovasculares; Complicaciones microvasculares; Control metabólicoType 1 diabetes; Lipid abnormalities; Atherogenic dyslipidemia; Macrovascular complications; Microvascular
Efecto metabólico del ejercicio físico regular en la población sana
Keywords: دیسیپیدمی آتروژنیک; Ejercicio físico; Resistencia a la insulina; Dislipidemia aterogénicaPhysical activity; Insulin resistance; Atherogenic dyslipidemia
Alteraciones del metabolismo de las lipoproteínas
Keywords: دیسیپیدمی آتروژنیک; Metabolismo lipoproteínas; Lípidos; Dislipemia aterógena; Lipoproteína (a); Transporte reverso del colesterolLipoprotein metabolism; Lipids; Atherogenic dyslipidemia; Lipoprotein (a); Reverse cholesterol transport
Atherogenic dyslipidemia in patients with established coronary artery disease
Keywords: دیسیپیدمی آتروژنیک; Coronary disease; Atherogenic dyslipidemia; HDL-cholesterol; Triglycerides
FABP4 predicts atherogenic dyslipidemia development. The PREDIMED study
Keywords: دیسیپیدمی آتروژنیک; Atherogenic dyslipidemia; FABP4; Predictive marker; PREDIMED;
Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels
Keywords: دیسیپیدمی آتروژنیک; Apolipoprotein B100; Atherogenic dyslipidemia; Diabetes; LDL-C; Non-HDL-C; Statins; Triglycerides
Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis
Keywords: دیسیپیدمی آتروژنیک; Fibrate; Cardiovascular disease; Coronary heart disease; Atherogenic dyslipidemia; Metaanalysis
Impact of metabolic syndrome and its severity on microvascular complications in type 2 diabetes
Keywords: دیسیپیدمی آتروژنیک; Type 2 diabetes; Metabolic syndrome; Microangiopathy; Atherogenic dyslipidemia
Usefulness of the triglyceride to high-density lipoprotein cholesterol ratio for predicting mortality risk in type 2 diabetes: Role of kidney dysfunction
Keywords: دیسیپیدمی آتروژنیک; Type 2 diabetes; Atherogenic dyslipidemia; TG/HDL-C ratio; Cardiovascular mortality
“Atherogenic index of plasma” (log10 triglyceride/high-density lipoprotein−cholesterol) predicts high blood pressure, diabetes, and vascular events
Keywords: دیسیپیدمی آتروژنیک; Atherogenic dyslipidemia; Coronary heart disease; Diabetes mellitus; Inflammation; Metabolic syndrome
Population variations in atherogenic dyslipidemia: A report from the HeartSCORE and IndiaSCORE Studies
Keywords: دیسیپیدمی آتروژنیک; Atherogenic dyslipidemia; Asian Indian; Blacks; Cardiovascular disease
Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study
Keywords: دیسیپیدمی آتروژنیک; Atherogenic dyslipidemia; Lipid subfractions; Low density lipoprotein; Pioglitazone; Simvastatin
The influence of polymorphism of −493G/T MTP gene promoter and metabolic syndrome on lipids, fatty acids and oxidative stress
Keywords: دیسیپیدمی آتروژنیک; Microsomal triglyceride transfer protein; Metabolic syndrome; Atherogenic dyslipidemia; Fatty acid profile; Oxidative stress
La diabetes mellitus tipo 2 como enfermedad cardiovascular
Keywords: دیسیپیدمی آتروژنیک; Diabetes mellitus tipo 2; Obesidad abdominal; Dislipidemia aterogénica; Sintetasa del óxido nÃtrico; Moléculas de adhesión; Type-2 diabetes mellitus; Visceral obesity; Atherogenic dyslipidemia; Nitric oxide synthase; Adhesion molecules; ACVA; acciden
Hypolipidemic therapy for the metabolic syndrome
Keywords: دیسیپیدمی آتروژنیک; Atherogenic dyslipidemia; Lipid-lowering agents; Cardiovascular disease; Statins; Fibrates
Management of the Metabolic Syndrome
Keywords: دیسیپیدمی آتروژنیک; Metabolic syndrome; Central obesity; Hyperglycemia; Atherogenic dyslipidemia; Raised blood pressure;